A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1227-1231, 2007.
Artigo
em Chinês
| WPRIM
| ID: wpr-268200
ABSTRACT
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase, originally identified as a protein kinase by its ability to phosphorylate and inactivate glycogen synthase. It was found that the overexpression of GSK-3 is associated with some diseases, such as diabetes, Alzheimer disease and other neurodegenerative diseases. Some pharmacological inhibitors of GSK-3 have been demonstrated to mimic insulin signaling, adjust glycogen synthesis and glucose metabolism, and improve insulin resistance. So GSK-3 inhibitors are realized as a new approach of treating diabetes. This review summarizes current advances in research of GSK-3 inhibitors as a new therapeutic approach for diabetes.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fisiologia
/
Glicemia
/
Resistência à Insulina
/
Transdução de Sinais
/
Quinase 3 da Glicogênio Sintase
/
Usos Terapêuticos
/
Diabetes Mellitus
/
Tratamento Farmacológico
/
Inibidores Enzimáticos
/
Doença de Alzheimer
Limite:
Animais
/
Humanos
Idioma:
Chinês
Revista:
Acta Pharmaceutica Sinica
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS